Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings
- Turning Point Therapeutics Inc (NASDAQ: TPTX) has reported initial data from the ongoing Phase 1/2 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations.
- Data from the Phase 1 dose-finding portion of the study showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile.
- TPX-0046 was generally well tolerated, with the most frequent treatment-emergent adverse event being mild to moderate dizziness.
- The maximum tolerated dose had not been determined, with one dose-limiting toxicity of treatment-related moderate gait disturbance at 30 mg dose.
- Of five RET TKI-naïve patients, four showed tumor regressions of -42%, -37%, -23%, and -3%, including two patients dosed at 30 mg who achieved confirmed partial responses with a duration of responses of 5.6 and 5.8+ months, respectively.
- Of 9 TKI-pretreated patients, three patients achieved tumor regressions of -44%, -27%, and -17%.
- The company also plans to revise the study protocol to include Phase 1 expansion cohorts in up to 75 patients with RET-altered malignancies.
- Price Action: TPTX shares are trading 0.50% lower at $89.50 in the premarket session on the last check Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs cancer Solid TumorBiotech News Health Care FDA General
